 Connection
Brian Freed to Receptors, Interleukin-2
This is a "connection" page, showing publications Brian Freed has written about Receptors, Interleukin-2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.186 |
|
|
|
-
McCue JM, Lazis S, John Cohen J, Modiano JF, Freed BM. Hydroquinone and catechol interfere with T cell cycle entry and progression through the G1 phase. Mol Immunol. 2003 Jun; 39(16):995-1001.
Score: 0.057
-
Geiselhart LA, Christian T, Minnear F, Freed BM. The cigarette tar component p-benzoquinone blocks T-lymphocyte activation by inhibiting interleukin-2 production, but not CD25, ICAM-1, or LFA-1 expression. Toxicol Appl Pharmacol. 1997 Mar; 143(1):30-6.
Score: 0.037
-
Li Q, Geiselhart L, Mittler JN, Mudzinski SP, Lawrence DA, Freed BM. Inhibition of human T lymphoblast proliferation by hydroquinone. Toxicol Appl Pharmacol. 1996 Aug; 139(2):317-23.
Score: 0.036
-
Geiselhart L, Conti DJ, Freed BM. RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Transplantation. 1996 Jun 15; 61(11):1637-42.
Score: 0.035
-
Freed BM, Lempert N, Lawrence DA. The inhibitory effects of N-ethylmaleimide, colchicine and cytochalasins on human T-cell functions. Int J Immunopharmacol. 1989; 11(5):459-65.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|